Carbetocin (ACP-101) is an investigational drug that binds with oxytocin receptors with greater sensitivity than oxytocin, a naturally occurring hormone. Carbetocin is not approved in the United States but is approved in some other countries for the treatment of women with excessive bleeding after giving birth via cesarean section.
In this Phase 3 study, carbetocin nasal spray or placebo will be inhaled through the nose three times each day. This study will last approximately 19 weeks and will involve up to 5 in-person visits to the study center. Eligible participants will be randomly assigned to study drug or placebo. Upon completion of the study treatments, participants are invited to join a long-term extension study in which all participants will receive carbetocin nasal spray for up to 36 months.
Study drug, clinic visits, and study-related procedures are provided at no cost. You may also be reimbursed for time and travel expenses.
Learn more about what you can expect should you choose to participate in this 20-minute webinar: Watch the Webinar Now!
Study Type: Interventional
Eligible Ages: 5-30 years
Trial Id:
Phase: 3
Duration: 19 weeks
Status: enrolling
Lead Sponsor: Acadia Therapeutics
Countries: United States
For an up-to-date list of trial sites, click here to visit the COMPASSPWS page.
UK Sites are now available! Visit COMPASSPWS UK to find a site near you!
Acadia has established a service to help connect families with Compass PWS trial sites. Can’t find a site near you? Acadia will help connect you to a site and cover all travel expenses! Visit the COMPASS PWS website and submit your contact information and a representative will contact you to help get the process started.